Literature DB >> 21289116

Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates.

Anne Schaap-Nutt1, Caraline Higgins, Emerito Amaro-Carambot, Sheila M Nolan, Christopher D'Angelo, Brian R Murphy, Peter L Collins, Alexander C Schmidt.   

Abstract

Human parainfluenza virus type 2 (HPIV-2), an important pediatric respiratory pathogen, encodes a V protein that inhibits type I interferon (IFN) induction and signaling. Using reverse genetics, we attempted the recovery of a panel of V mutant viruses that individually contained one of six cysteine-to-serine (residues 193, 197, 209, 211, 214, and 218) substitutions, one of two paired charge-to-alanine (R175A/R176A and R205A/K206A) substitutions, or a histidine-to-phenylalanine (H174F) substitution. This mutagenesis was performed using a cDNA-derived HPIV-2 virus that expressed the V and P coding sequences from separate mRNAs. Of the cysteine substitutions, only C193S, C214S, and C218S yielded viable virus, and only the C214S mutant replicated well enough for further analysis. The H174F, R175A/R176A, and R205A/K206A mutants were viable and replicated well. The H174F and R205A/K206A mutants did not differ from the wild-type (WT) V in their ability to physically interact with MDA5, a cytoplasmic sensor of nonself RNA that induces type I IFN. Like WT HPIV-2, these mutants inhibited IFN-β induction and replicated efficiently in African green monkeys (AGMs). In contrast, the C214S and R175A/R176A mutants did not bind MDA5 efficiently, did not inhibit interferon regulatory factor 3 (IRF3) dimerization or IFN-β induction, and were attenuated in AGMs. These findings indicate that V binding to MDA5 is important for HPIV-2 virulence in nonhuman primates and that some V protein residues involved in MDA5 binding are not essential for efficient HPIV-2 growth in vitro. Using a transient expression system, 20 additional mutant V proteins were screened for MDA5 binding, and the region spanning residues 175 to 180 was found to be essential for this activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21289116      PMCID: PMC3126142          DOI: 10.1128/JVI.02542-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production.

Authors:  J M Emeny; M J Morgan
Journal:  J Gen Virol       Date:  1979-04       Impact factor: 3.891

2.  Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.

Authors:  Josephine M McAuliffe; Sonja R Surman; Jason T Newman; Jeffrey M Riggs; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

3.  The V proteins of simian virus 5 and other paramyxoviruses inhibit induction of interferon-beta.

Authors:  Emma Poole; Biao He; Robert A Lamb; Richard E Randall; Stephen Goodbourn
Journal:  Virology       Date:  2002-11-10       Impact factor: 3.616

4.  Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis.

Authors:  J D Mosca; P M Pitha
Journal:  Mol Cell Biol       Date:  1986-06       Impact factor: 4.272

Review 5.  Current approaches to the development of vaccines effective against parainfluenza viruses.

Authors:  B R Murphy
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

6.  Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus.

Authors:  Leonid Gitlin; Winfried Barchet; Susan Gilfillan; Marina Cella; Bruce Beutler; Richard A Flavell; Michael S Diamond; Marco Colonna
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-19       Impact factor: 11.205

7.  Extensive antigenic diversity among human parainfluenza type 2 virus isolates and immunological relationships among paramyxoviruses revealed by monoclonal antibodies.

Authors:  M Tsurudome; M Nishio; H Komada; H Bando; Y Ito
Journal:  Virology       Date:  1989-07       Impact factor: 3.616

8.  C and V proteins of Sendai virus target signaling pathways leading to IRF-3 activation for the negative regulation of interferon-beta production.

Authors:  Takayuki Komatsu; Kenji Takeuchi; Junko Yokoo; Bin Gotoh
Journal:  Virology       Date:  2004-07-20       Impact factor: 3.616

9.  Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.

Authors:  Jason T Newman; Jeffrey M Riggs; Sonja R Surman; Josephine M McAuliffe; Teresa A Mulaikal; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

10.  VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Authors:  David F Stojdl; Brian D Lichty; Benjamin R tenOever; Jennifer M Paterson; Anthony T Power; Shane Knowles; Ricardo Marius; Jennifer Reynard; Laurent Poliquin; Harold Atkins; Earl G Brown; Russell K Durbin; Joan E Durbin; John Hiscott; John C Bell
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

View more
  11 in total

1.  Paramyxovirus V proteins interact with the RNA Helicase LGP2 to inhibit RIG-I-dependent interferon induction.

Authors:  Kay Childs; Richard Randall; Stephen Goodbourn
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

Review 2.  Paramyxovirus evasion of innate immunity: Diverse strategies for common targets.

Authors:  Michelle D Audsley; Gregory W Moseley
Journal:  World J Virol       Date:  2013-05-12

Review 3.  Interplay between innate immunity and negative-strand RNA viruses: towards a rational model.

Authors:  Denis Gerlier; Douglas S Lyles
Journal:  Microbiol Mol Biol Rev       Date:  2011-09       Impact factor: 11.056

Review 4.  Pathogenesis of acute respiratory illness caused by human parainfluenza viruses.

Authors:  Henrick Schomacker; Anne Schaap-Nutt; Peter L Collins; Alexander C Schmidt
Journal:  Curr Opin Virol       Date:  2012-03-03       Impact factor: 7.090

Review 5.  Progress in respiratory virus vaccine development.

Authors:  Alexander C Schmidt
Journal:  Semin Respir Crit Care Med       Date:  2011-08-19       Impact factor: 3.119

6.  African green monkeys recapitulate the clinical experience with replication of live attenuated pandemic influenza virus vaccine candidates.

Authors:  Yumiko Matsuoka; Amorsolo Suguitan; Marlene Orandle; Myeisha Paskel; Kobporn Boonnak; Donald J Gardner; Friederike Feldmann; Heinz Feldmann; Michael Marino; Hong Jin; George Kemble; Kanta Subbarao
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

7.  The neutralizing capacity of antibodies elicited by parainfluenza virus infection of African Green Monkeys is dependent on complement.

Authors:  Anne E Mayer; John B Johnson; Griffith D Parks
Journal:  Virology       Date:  2014-05-29       Impact factor: 3.616

8.  Human parainfluenza virus serotypes differ in their kinetics of replication and cytokine secretion in human tracheobronchial airway epithelium.

Authors:  Anne Schaap-Nutt; Rachael Liesman; Emmalene J Bartlett; Margaret A Scull; Peter L Collins; Raymond J Pickles; Alexander C Schmidt
Journal:  Virology       Date:  2012-09-07       Impact factor: 3.616

9.  The V protein of Tioman virus is incapable of blocking type I interferon signaling in human cells.

Authors:  Grégory Caignard; Marianne Lucas-Hourani; Kevin P Dhondt; Jean-Louis Labernardière; Thierry Petit; Yves Jacob; Branka Horvat; Frédéric Tangy; Pierre-Olivier Vidalain
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

10.  Co-Circulation and Excretion Dynamics of Diverse Rubula- and Related Viruses in Egyptian Rousette Bats from South Africa.

Authors:  Marinda Mortlock; Muriel Dietrich; Jacqueline Weyer; Janusz T Paweska; Wanda Markotter
Journal:  Viruses       Date:  2019-01-08       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.